Predictive value of soluble urokinase-type plasminogen activator receptor in patients with severe acute pancreatitis

Abstract

Objective To explore the predictive value of soluble urokinase-type plasminogen activator receptor (suPAR) for severe acute pancreatitis (SAP). Methods A prospective cohort study was designed to enroll 103 patients with acute pancreatitis who were admitted to our department from March 1 to June 1, 2021, including 23 SAP and 80 non-severe acute pancreatitis (NSAP). Another 30 healthy subjects were recruited concurrently as control group. The plasma samples of all subjects were collected on the first day of admission to detect the level of suPAR using ELISA. General clinical data and the levels of procalcitonin (PCT), interleukin-6 (IL-6), C-reactive protein (CRP), D-dimer and serum calcium (Ca2+), as well as the results of blood routine and biochemical examinations of patients were all collected. Acute Physiology and Chronic Health Evaluation (APACHEⅡ) score and Ranson's score were subsequently calculated. For the control subjects, only their demographic characteristics (age and gender) were collected. Statistical analysis was adopted on the above data. Results The plasma suPAR level was significantly higher in the patients with NSAP and SAP than the control group (P < 0.05), and also notably higher in those of the SAP group than those out of the NSAP patients (P < 0.05). Pearson correlation analysis showed that plasma suPAR level was positively correlated with both APACHE Ⅱ score and Ranson's score (R=0.554, R=0.485, P < 0.05). Multivariate Logistic regression analysis indicated that suPAR, D-dimer and Ca2+ levels were independent predictors of SAP. ROC curve demonstrated that serum suPAR had a good predictive value for SAP (AUC=0.869). Conclusion The plasma level of suPAR is closely correlated with the severity of acute pancreatitis, and plays an important role in prediction of SAP.

Keywords

• acute pancreatitis
• soluble urokinase-type plasminogen activator receptor
• severity